论文部分内容阅读
目的 :探讨 CD44 V6 表达与恶性卵巢上皮性肿瘤发生、发展及预后的关系。方法 :采用免疫组化 S- P方法 ,检测 2 0例良性、10例交界性及 5 5例恶性卵巢上皮性肿瘤组织 CD44 V6 的表达 ,并分析其与临床病理指标间的关系。结果 :(1) CD44 V6 表达阳性率及强度随良性、交界性、恶性卵巢上皮性肿瘤的进展而逐渐增加 ,差异有显著性 (P=0 .0 0 1,P强 =0 .0 13) ;在良性卵巢上皮性肿瘤中表达阳性率及强度均低于卵巢上皮性癌 (P=0 .0 0 0 ,P强 =0 .0 0 8)。(2 ) CD44 V6 的表达阳性率与卵巢癌的临床分期、淋巴结转移及腹水均无关 (P=0 .2 44 ,0 .0 72 ,0 .0 5 1) ;而表达强度与卵巢癌的临床分期 ,淋巴结转移及腹水有关 (P强 =0 .0 0 4,0 .0 0 1,0 .0 2 5 ) ;表达阳性率及强度与病理类型、组织分化均无关 (P=0 .134,0 .2 31;P强 =0 .186 ,1.0 0 0 )。 (3) CD44 V6 的阳性表达与卵巢癌的预后有关 (P=0 .0 42 ) ,表达越强 ,预后越差。结论 :CD44 V6 表达与卵巢癌的发生及转移密切相关。检测 CD44 V6 的表达有助于预测卵巢癌的进展程度、淋巴结转移趋势以及估计预后、指导治疗
Objective: To investigate the relationship between the expression of CD44 V6 and the occurrence, development and prognosis of malignant ovarian epithelial neoplasm. Methods: The expression of CD44 V6 in 20 cases of benign, 10 cases of borderline and 55 cases of malignant ovarian epithelial tumors was detected by immunohistochemical S-P method. The relationship between the expression of CD44 V6 and clinicopathological parameters was analyzed. Results: (1) The positive rate and intensity of CD44 V6 expression gradually increased with the progression of benign, borderline and malignant ovarian epithelial tumors, the difference was significant (P = 0.010, P = 0.013) ; The positive rate and intensity of expression in benign ovarian epithelial tumors were lower than that in epithelial ovarian cancer (P = 0.0000, P = 0.080). (2) The positive rate of CD44 V6 was not associated with the clinical stage, lymph node metastasis and ascites of ovarian cancer (P = 0.44, 0.72, 0. 051) Staging, lymph node metastasis and ascites (P = 0.040, 0.010, 0.025). The positive rate and intensity of expression were not associated with pathological type and histological differentiation (P = 0.134, 0 .2 31; P strong = 0 .186, 1.0 0 0). (3) The positive expression of CD44 V6 was related to the prognosis of ovarian cancer (P = 0.042). The stronger the expression, the worse the prognosis. Conclusion: The expression of CD44 V6 is closely related to the occurrence and metastasis of ovarian cancer. Detecting the expression of CD44 V6 can help predict the progression of ovarian cancer, the trend of lymph node metastasis and the prognosis of prognosis, and guide the treatment